Mon, 02 Nov 2026
10:55:57 am
Rudransh Sangwan
Published at: September 18, 2026, 5:22 AM
Synopsis
Tata Chemicals shares came under pressure amid fresh Tata Sons developments. Check why the stock fell, its Tata Sons stake and key factors investors are watching.

Tata Chemicals share price fell as much as 7.8% on September 18. Tata Investment Corporation and Tata Motors Passenger Vehicles also came under pressure.
The fall followed fresh developments around Tata Sons, including its proposed listing, N Chandrasekaran's five year reappointment and opposition from Tata Trusts.
| Metric | Tata Chemicals |
|---|---|
| Early share price | Around Rs 713 to Rs 723 |
| Early fall | Around 7% to 8% |
| 52 week high | Around Rs 1,000 |
| 52 week low | Around Rs 650 |
| NSE ticker | TATACHEM |
Reuters reported that Tata Chemicals fell as much as 7.8% in early trade. Tata Investment Corporation fell 3.9%, while Tata Motors Passenger Vehicles declined 2.6%.
Loading chart...
| Reason | Impact |
|---|---|
| Tata Sons listing dispute | Increased uncertainty around Tata Group holdings |
| Tata Trusts opposition | Raised questions over the proposed listing |
| SP Group stake proposal | Added another development around Tata Sons ownership |
| Profit booking | Reversed part of Thursday's sharp gains |
| Tata Group selling | Put pressure on companies holding Tata Sons stakes |
Tata Trusts said it had not agreed to take Tata Sons public and called for all available options to be examined.
The selling also reversed part of Thursday's gains in Tata Group stocks.
Tata Chemicals holds a stake in Tata Sons, making developments around the holding company important for investors.
Moneycontrol reported that Tata Chemicals holds about 2.53% in Tata Sons. ICICI Securities estimated the value of this stake at around Rs 10,000 crore to Rs 15,000 crore.
A Tata Sons listing could affect the value assigned to this holding, while the ongoing dispute has added uncertainty.
| Tata stock | Early move |
|---|---|
| Tata Chemicals | Around -7.8% |
| Tata Investment Corporation | Around -3.9% |
| Tata Motors Passenger Vehicles | Around -2.6% |
| Tata Power | Around -1.4% |
| TCS | Around -2.4% |
The decline followed Thursday's gains after Tata Sons announced Chandrasekaran's five year reappointment and listing related plans.
Tata Sons' board approved a fresh five year term for N Chandrasekaran and decided to begin steps for a potential public listing.
Tata Trusts has opposed both developments. Noel Tata has questioned the validity of the reappointment and said Tata Trusts has not agreed to the listing.
The Shapoorji Pallonji Group has also proposed monetising part of its Tata Sons stake through a buyout in two tranches over 18 months. The proposal could generate at least Rs 25,000 crore.
| Factor | What to track |
|---|---|
| Tata Chemicals | Share price and trading volume |
| Tata Sons | Listing related decisions |
| Tata Trusts | Further statements or actions |
| RBI | Regulatory developments |
| SP Group | Stake monetisation proposal |
| Tata Group stocks | Further sector wide selling |
| Metric | Value |
|---|---|
| Market Cap | Rs 18,217 crore |
| Current Price | Rs 715 |
| Day Change | -8.37% |
| High / Low | Rs 1,002 / Rs 580 |
| Book Value | Rs 832 |
| Dividend Yield | 1.53% |
| ROCE | 3.42% |
| ROE | 1.27% |
| Face Value | Rs 10 |
Tata Chemicals share price remains closely watched as developments around Tata Sons continue. Investors will track further decisions from Tata Sons, Tata Trusts and regulators.

Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
No related topics available

Motilal Oswal Q2 FY27 results show net profit rising 198% to ₹1,080 crore, revenue increasing 64% to ₹3,040 crore and EBITDA margin reaching 60.37%.

Bliss GVS Pharma Q2 FY27 results show revenue rising 37.3% to ₹261.13 crore, EBITDA jumping 161.4% and net profit increasing 196%.

Alivus Life Sciences Q2 FY27 results show net profit rising 51.3% to ₹196.8 crore, revenue growing 16% to ₹682 crore and EBITDA margin reaching 38.

Thyrocare Q2 FY27 revenue rose 25.1% to ₹270.81 crore, while net profit fell 66.9% to ₹15.89 crore amid a ₹44.98 crore impairment loss.

Patel Retail will invest ₹2 crore to add 20,000 sq ft to its Ambernath distribution centre, increasing covered area to 84,000 sq ft.